P

Piramal Pharma Ltd
NSE:PPLPHARMA

Watchlist Manager
Piramal Pharma Ltd
NSE:PPLPHARMA
Watchlist
Price: 249.5 INR 0.26%
Market Cap: 330.8B INR
Have any thoughts about
Piramal Pharma Ltd?
Write Note

Intrinsic Value

The intrinsic value of one PPLPHARMA stock under the Base Case scenario is 139.65 INR. Compared to the current market price of 249.5 INR, Piramal Pharma Ltd is Overvalued by 44%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

PPLPHARMA Intrinsic Value
139.65 INR
Overvaluation 44%
Intrinsic Value
Price
P
Worst Case
Base Case
Best Case

Valuation Backtest
Piramal Pharma Ltd

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for PPLPHARMA cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about PPLPHARMA?
Bearish
Neutral
Bullish

Fundamental Analysis

Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Investment Journal
AI Assistant
AI Assistant
Ask me anything about Piramal Pharma Ltd

Provide an overview of the primary business activities
of Piramal Pharma Ltd.

What unique competitive advantages
does Piramal Pharma Ltd hold over its rivals?

What risks and challenges
does Piramal Pharma Ltd face in the near future?

Summarize the latest earnings call
of Piramal Pharma Ltd.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Piramal Pharma Ltd.

Provide P/S
for Piramal Pharma Ltd.

Provide P/E
for Piramal Pharma Ltd.

Provide P/OCF
for Piramal Pharma Ltd.

Provide P/FCFE
for Piramal Pharma Ltd.

Provide P/B
for Piramal Pharma Ltd.

Provide EV/S
for Piramal Pharma Ltd.

Provide EV/GP
for Piramal Pharma Ltd.

Provide EV/EBITDA
for Piramal Pharma Ltd.

Provide EV/EBIT
for Piramal Pharma Ltd.

Provide EV/OCF
for Piramal Pharma Ltd.

Provide EV/FCFF
for Piramal Pharma Ltd.

Provide EV/IC
for Piramal Pharma Ltd.

Show me price targets
for Piramal Pharma Ltd made by professional analysts.

What are the Revenue projections
for Piramal Pharma Ltd?

How accurate were the past Revenue estimates
for Piramal Pharma Ltd?

What are the Net Income projections
for Piramal Pharma Ltd?

How accurate were the past Net Income estimates
for Piramal Pharma Ltd?

What are the EPS projections
for Piramal Pharma Ltd?

How accurate were the past EPS estimates
for Piramal Pharma Ltd?

What are the EBIT projections
for Piramal Pharma Ltd?

How accurate were the past EBIT estimates
for Piramal Pharma Ltd?

Compare the revenue forecasts
for Piramal Pharma Ltd with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Piramal Pharma Ltd and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Piramal Pharma Ltd against its competitors.

Analyze the profit margins
(gross, operating, and net) of Piramal Pharma Ltd compared to its peers.

Compare the P/E ratios
of Piramal Pharma Ltd against its peers.

Discuss the investment returns and shareholder value creation
comparing Piramal Pharma Ltd with its peers.

Analyze the financial leverage
of Piramal Pharma Ltd compared to its main competitors.

Show all profitability ratios
for Piramal Pharma Ltd.

Provide ROE
for Piramal Pharma Ltd.

Provide ROA
for Piramal Pharma Ltd.

Provide ROIC
for Piramal Pharma Ltd.

Provide ROCE
for Piramal Pharma Ltd.

Provide Gross Margin
for Piramal Pharma Ltd.

Provide Operating Margin
for Piramal Pharma Ltd.

Provide Net Margin
for Piramal Pharma Ltd.

Provide FCF Margin
for Piramal Pharma Ltd.

Show all solvency ratios
for Piramal Pharma Ltd.

Provide D/E Ratio
for Piramal Pharma Ltd.

Provide D/A Ratio
for Piramal Pharma Ltd.

Provide Interest Coverage Ratio
for Piramal Pharma Ltd.

Provide Altman Z-Score Ratio
for Piramal Pharma Ltd.

Provide Quick Ratio
for Piramal Pharma Ltd.

Provide Current Ratio
for Piramal Pharma Ltd.

Provide Cash Ratio
for Piramal Pharma Ltd.

What is the historical Revenue growth
over the last 5 years for Piramal Pharma Ltd?

What is the historical Net Income growth
over the last 5 years for Piramal Pharma Ltd?

What is the current Free Cash Flow
of Piramal Pharma Ltd?

Discuss the annual earnings per share (EPS)
trend over the past five years for Piramal Pharma Ltd.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Revenue & Expenses Breakdown
Piramal Pharma Ltd

Balance Sheet Decomposition
Piramal Pharma Ltd

Current Assets 53.8B
Cash & Short-Term Investments 4.5B
Receivables 18.3B
Other Current Assets 31B
Non-Current Assets 98.6B
Long-Term Investments 2.5B
PP&E 49.2B
Intangibles 41.8B
Other Non-Current Assets 5.1B
Current Liabilities 52.4B
Accounts Payable 13.4B
Other Current Liabilities 39B
Non-Current Liabilities 21B
Long-Term Debt 16.4B
Other Non-Current Liabilities 4.5B
Efficiency

Earnings Waterfall
Piramal Pharma Ltd

Revenue
87B INR
Cost of Revenue
-31.6B INR
Gross Profit
55.4B INR
Operating Expenses
-27.8B INR
Operating Income
27.6B INR
Other Expenses
-27.2B INR
Net Income
453.3m INR

Free Cash Flow Analysis
Piramal Pharma Ltd

Last Value
3-Years Average
FCF Margin
Conversion Rate
Earnings Calls

Piramal Pharma announced an impressive 17% revenue growth in Q2, supported by a robust CDMO sector, which saw a remarkable 24% surge. EBITDA margins expanded by 150 basis points to 18%. Future growth prospects remain optimistic, with guidance for early teen revenue growth targeted for FY '30, aiming for a $2 billion revenue milestone and a 25% EBITDA margin. The company is investing $80 million to enhance its Lexington facility, significantly upping its capacity for sterile injectable products, responding to rising market demand. With considerable order inflow and strategic initiatives, the company is set to continue its positive trajectory.

What is Earnings Call?
Fundamental Scores

PPLPHARMA Profitability Score
Profitability Due Diligence

Piramal Pharma Ltd's profitability score is 50/100. The higher the profitability score, the more profitable the company is.

Positive Gross Profit
Positive Operating Income
Positive Revenue Growth Forecast
Positive Free Cash Flow
50/100
Profitability
Score

Piramal Pharma Ltd's profitability score is 50/100. The higher the profitability score, the more profitable the company is.

PPLPHARMA Solvency Score
Solvency Due Diligence

Piramal Pharma Ltd's solvency score is 55/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Low D/E
Long-Term Solvency
Short-Term Solvency
55/100
Solvency
Score

Piramal Pharma Ltd's solvency score is 55/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

PPLPHARMA Price Targets Summary
Piramal Pharma Ltd

Wall Street analysts forecast PPLPHARMA stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for PPLPHARMA is 284.58 INR with a low forecast of 262.6 INR and a high forecast of 325.5 INR.

Lowest
Price Target
262.6 INR
5% Upside
Average
Price Target
284.58 INR
14% Upside
Highest
Price Target
325.5 INR
30% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for PPLPHARMA?

Click here to dive deeper.

Dividends

Dividend Yield
Lowest
Average
Highest
Dividend Per Share
N/A
Growth 3Y
Growth 5Y
Growth 10Y
Dividend Safety Score
Very
Unsafe
Unsafe
Safe
Very
Safe
0
25
50
75
100
Shareholder Yield

Current shareholder yield for PPLPHARMA is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
Lowest
Average
Highest
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Profile

Piramal Pharma Ltd

Country

India

Industry

Pharmaceuticals

Market Cap

329.3B INR

Dividend Yield

0.04%

Description

Piramal Pharma Ltd. engages in development and manufacturing of pharmaceutical products. The company is headquartered in Mumbai, Maharashtra and currently employs 0 full-time employees. The company went IPO on 2022-10-19. The firm has approximately 15 global facilities and a global distribution network in over 100 countries. The firm's subsidiaries include Piramal Pharma Solutions (PPS), an integrated contract development and manufacturing organization; Piramal Critical Care (PCC), a complex hospital generics business, and the India consumer healthcare business selling over-the-counter products. PPS offers end-to-end development and manufacturing solutions through a globally integrated network of facilities across the drug life cycle to generic companies. PCC's complex hospital product portfolio includes inhalation anesthetics, intrathecal therapies for spasticity and pain management, injectable pain and anesthetics, injectable anti-infectives, and other therapies.

Contact

MAHARASHTRA
Mumbai
Gr. Flr.,Piramal Ananta, Agastya Corporate Park,, Kamani Junction, LBS Marg, Kurla (West)
www.piramal.com

IPO

2022-10-19

Employees

-

Officers

Executive Chairperson
Ms. Nandini Ajay Piramal
President, CFO & Executive Whole-Time Director
Mr. Vivek Valsaraj
Company Secretary & Compliance Officer
Ms. Tanya Sanish
CEO of Piramal Global Pharma & Director
Mr. Peter Daniel DeYoung
Senior Vice President of Operations
Vinay Agarwal
Head of Investor Relations & Sustainability
Mr. Gagan Borana
Show More
Vice President of Marketing
Sameer Penkar
Vice President of Sales
Prashanth M. S.
Senior Vice President of Human Resources
Mr. Vikram Duggal
Executive Vice President of India & UK Formulations
Mr. Debashish Chakravorty
Show Less

See Also

Discover More
What is the Intrinsic Value of one PPLPHARMA stock?

The intrinsic value of one PPLPHARMA stock under the Base Case scenario is 139.65 INR.

Is PPLPHARMA stock undervalued or overvalued?

Compared to the current market price of 249.5 INR, Piramal Pharma Ltd is Overvalued by 44%.

Back to Top